These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14725787)

  • 21. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA).
    Arora M; Kumar A; Das SN; Srivastava LM
    Clin Exp Immunol; 1998 Jan; 111(1):102-6. PubMed ID: 9472668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
    Ninomiya H; Kobayashi T; Abe T
    Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions.
    Harris CL; Lublin DM; Morgan BP
    J Immunol Methods; 2002 Oct; 268(2):245-58. PubMed ID: 12215393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The serum resistance of malaria-infected erythrocytes.
    Kawamoto Y; Kojima K; Hitsumoto Y; Okada H; Holers VM; Miyama A
    Immunology; 1997 May; 91(1):7-12. PubMed ID: 9203959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
    Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
    Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.
    Thomas TC; Rollins SA; Rother RP; Giannoni MA; Hartman SL; Elliott EA; Nye SH; Matis LA; Squinto SP; Evans MJ
    Mol Immunol; 1996 Dec; 33(17-18):1389-401. PubMed ID: 9171898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced complement-susceptibility and dysfunction of lymphocytes in paroxysmal nocturnal haemoglobinuria (PNH).
    Tomiyama J; Ninomiya H; Abe T
    Br J Haematol; 1990 Dec; 76(4):540-4. PubMed ID: 1702310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury.
    van Denderen BJ; Salvaris E; Romanella M; Aminian A; Katerelos M; Tange MJ; Pearse MJ; d'Apice AJ
    Transplantation; 1997 Sep; 64(6):882-8. PubMed ID: 9326415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.
    Evans MJ; Rollins SA; Wolff DW; Rother RP; Norin AJ; Therrien DM; Grijalva GA; Mueller JP; Nye SH; Squinto SP
    Mol Immunol; 1995 Nov; 32(16):1183-95. PubMed ID: 8559143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
    Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
    J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robust in vitro replication of Plasmodium falciparum in glycosyl-phosphatidylinositol-anchored membrane glycoprotein-deficient red blood cells.
    Pattanapanyasat K; Walsh DS; Yongvanitchit K; Piyawatthanasakul N; Wanachiwanawin W; Webster HK
    Am J Trop Med Hyg; 2003 Oct; 69(4):360-5. PubMed ID: 14640493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.
    Terstappen LW; Nguyen M; Lazarus HM; Medof ME
    J Leukoc Biol; 1992 Dec; 52(6):652-60. PubMed ID: 1281489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
    Harris CL; Williams AS; Linton SM; Morgan BP
    Clin Exp Immunol; 2002 Aug; 129(2):198-207. PubMed ID: 12165074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.